When semaglutide was approved in the UK — and what changed since

You've seen semaglutide everywhere lately, here's what the approval record actually shows

Semaglutide's rise from a diabetes drug to a headline weight-loss medicine felt sudden to most people, but the regulatory journey stretched across several years. The molecule was already known to clinicians managing type 2 diabetes through Ozempic, which received its UK licence for that indication well before Wegovy appeared. When the MHRA first approved Wegovy for weight management in 2021, it was licensed at a 2.4 mg weekly injection dose, accompanied by a stepped titration schedule starting at 0.25 mg to help the body adjust. That step-up approach (spending roughly four weeks at each rung before the prescriber moves you on) remains the basis of the programme today.

NICE then evaluated semaglutide for weight management and published its recommendation (TA875) in March 2023. Under that appraisal, NHS access is conditional on treatment within a specialist weight management service, a BMI of 35 or above (or 30–34.9 where specialist-referral criteria apply), at least one weight-related condition, and a two-year maximum treatment duration. Ethnic-background adjustments lower the relevant BMI thresholds by 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean populations. If less than five percent of body weight is lost after six months on the maintenance dose, continuing is reviewed. Those NHS criteria are deliberately narrow; the MHRA licence itself covers a broader private-prescription population, which is where a regulated online pharmacy like the Wegovy service at nume sits.

For a fuller breakdown of the original licence and what came with it, the detailed approval page covers the MHRA's exact decision.

January 2026, April 2026, June 2026, three approvals in six months

The pace of regulatory activity around semaglutide accelerated sharply in the first half of 2026. In January, the MHRA approved a higher 7.2 mg maintenance dose, initially supplied as three 2.4 mg pens administered in a single weekly session. Then, on 14 April 2026, the regulator approved a dedicated single-dose 7.2 mg pen: one injection per week, with a built-in covered needle that locks after use. Trials reported around 20.7% average weight loss over 72 weeks at the 7.2 mg dose, narrowing the gap with the highest tirzepatide dose. That pen is licensed for adults with a BMI of 30 or above; it is not indicated for people with a BMI below that threshold, and the starting dose remains 0.25 mg regardless, with the prescriber guiding any increases. Whether a specific dose or pen format is available is something confirmed at consultation, stock and clinical suitability both factor in.

The bigger headline, though, landed on 11 June 2026: the MHRA approved Wegovy tablets, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet is co-formulated with an absorption enhancer and is taken once daily, first thing in the morning, on an empty stomach, with a small amount of plain water, then nothing else for at least thirty minutes. The maintenance dose is 25 mg, reached by stepping through 1.5 mg, 4 mg and 9 mg over roughly four months. Clinical trial data (OASIS 4, 64 weeks) showed around 13.6% average weight loss against placebo; among participants who stayed fully adherent throughout the trial, that figure was approximately 16.6%. The tablet requires no refrigeration, which many people find practically useful, it sits in a cupboard rather than the fridge door. If you want the detail on exactly which semaglutide formulations are approved for weight loss, and which are only licensed for diabetes, that page separates them clearly.

Ozempic, Rybelsus and the indications semaglutide does NOT cover for weight loss

One source of persistent confusion is that semaglutide exists under several brand names in the UK, each carrying a different licence. Ozempic (0.5 mg, 1 mg and 2 mg injections) is licensed for type 2 diabetes, not weight management. It is not an alternative route to Wegovy; prescribing it for weight loss is off-label and it is not something a legitimate regulated pharmacy offers in that context. Rybelsus is the oral semaglutide tablet approved for type 2 diabetes, at 3 mg, 7 mg and 14 mg doses. Those strengths are entirely separate from the Wegovy tablet schedule (1.5 mg, 4 mg, 9 mg, 25 mg) and should never be confused with it. The 14 mg semaglutide page explains that distinction for people who encounter that dose in a diabetes context.

Then there is the MASH approval. On 3 July 2026, the MHRA granted conditional approval for semaglutide (Wegovy) to treat metabolic dysfunction-associated steatohepatitis (a form of fatty liver disease) in adults with moderate-to-advanced fibrosis, as confirmed by the GOV.UK announcement from 3 July 2026. For more context on that indication, the MASH approval page covers the background. Prescribing for MASH is a separate clinical decision from weight management; at nume, the focus is the weight-loss licence.

The NHS approval timeline for weight management purposes is documented on the semaglutide approval date page if you want a reference you can cite directly.

What the approval timeline means for people considering treatment now

The speed of approvals across 2025 and 2026 has left many people unsure what is actually available, what is genuinely licensed and what they might have seen advertised without a proper prescription. A medicine's MHRA approval is the legal starting point, not the end of the process, a prescriber still needs to assess your individual picture before any prescription is issued. As of summer 2026, the licensed options for weight management are the Wegovy injection (up to 7.2 mg) and the Wegovy tablet (up to 25 mg), both available only on prescription. NHS access remains phased and subject to strict eligibility criteria. Private treatment through a GPhC-registered pharmacy is the practical route for people outside those criteria or unwilling to wait.

One thing worth noting if timing is on your mind: orders placed with a working-day cut-off (ours is 12pm, Monday to Friday) are reviewed the same day by a real prescriber, not software. If approval falls around a bank holiday or payday week when demand spikes, a small amount of forward planning saves a wait. You can read about where Wegovy is available from a regulated UK source, or explore the full treatment options and speak to our prescribers about whether semaglutide fits your situation. The NICE appraisal TA875 covers the clinical evidence base that underpins the recommendation.